Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease

Adipose tissue accumulation in specific body compartments has been associated with diabetes, hypertension and dyslipidemia. Perirenal fat (PRF) may lead to have direct lipotoxic effects on renal function and intrarenal hydrostatic pressure. This study was undertaken to explore the association of PRF...

Full description

Autores:
D´Marco, Luis
Salazar, Juan
Cortez, Marie
Salazar, María
Lima-Martínez, Marcos
Rojas, Edward
Roque, Willy
Bermúdez, Valmore
Wettel, Marjorie
Tipo de recurso:
Fecha de publicación:
2019
Institución:
Universidad Simón Bolívar
Repositorio:
Repositorio Digital USB
Idioma:
eng
OAI Identifier:
oai:bonga.unisimon.edu.co:20.500.12442/3660
Acceso en línea:
https://hdl.handle.net/20.500.12442/3660
Palabra clave:
Cardiovascular
Chronic kidney disease
Metabolic risk
Perirenal fat
Renal insufficiency
Diabetes
Rights
License
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
id USIMONBOL2_d8d0906f7fc14f38de7bb89c5ee3990c
oai_identifier_str oai:bonga.unisimon.edu.co:20.500.12442/3660
network_acronym_str USIMONBOL2
network_name_str Repositorio Digital USB
repository_id_str
dc.title.eng.fl_str_mv Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease
title Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease
spellingShingle Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease
Cardiovascular
Chronic kidney disease
Metabolic risk
Perirenal fat
Renal insufficiency
Diabetes
title_short Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease
title_full Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease
title_fullStr Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease
title_full_unstemmed Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease
title_sort Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease
dc.creator.fl_str_mv D´Marco, Luis
Salazar, Juan
Cortez, Marie
Salazar, María
Lima-Martínez, Marcos
Rojas, Edward
Roque, Willy
Bermúdez, Valmore
Wettel, Marjorie
dc.contributor.author.spa.fl_str_mv D´Marco, Luis
Salazar, Juan
Cortez, Marie
Salazar, María
Lima-Martínez, Marcos
Rojas, Edward
Roque, Willy
Bermúdez, Valmore
dc.contributor.author.eng.fl_str_mv Wettel, Marjorie
dc.subject.eng.fl_str_mv Cardiovascular
Chronic kidney disease
Metabolic risk
Perirenal fat
Renal insufficiency
topic Cardiovascular
Chronic kidney disease
Metabolic risk
Perirenal fat
Renal insufficiency
Diabetes
dc.subject.spa.fl_str_mv Diabetes
description Adipose tissue accumulation in specific body compartments has been associated with diabetes, hypertension and dyslipidemia. Perirenal fat (PRF) may lead to have direct lipotoxic effects on renal function and intrarenal hydrostatic pressure. This study was undertaken to explore the association of PRF with cardiovascular risk factors and different stages of chronic kidney disease (CKD). We studied 103 patients with CKD of different stages (1 to 5). PRF was measured by B-mode renal ultrasonography in the distal third between the cortex and the hepatic border and/or spleen. The PRF thickness was greater in CKD patients with impaired fasting glucose than in those with normal glucose levels (1.10 ± 0.40 cm vs. 0.85 ± 0.39 cm, P < 0.01). Patients in CKD stages 4 and 5 (glomerular filtration rate [GFR] < 30 mL/min/1.73 m2) had the highest PRF thickness. Serum triglyceride levels correlated positively with the PRF thickness; the PRF thickness was greater in patients with triglyceride levels ≥ 150 mg/dL (1.09 ± 0.40 cm vs. 0.86 ± 0.36 cm, P < 0.01). In patients with a GFR < 60 mL/min/1.73 m2, uric acid levels correlated positively with the PRF thickness (P < 0.05). In CKD patients, the PRF thickness correlated significantly with metabolic risk factors that could affect kidney function.
publishDate 2019
dc.date.accessioned.none.fl_str_mv 2019-08-08T15:03:04Z
dc.date.available.none.fl_str_mv 2019-08-08T15:03:04Z
dc.date.issued.none.fl_str_mv 2019
dc.type.eng.fl_str_mv article
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv 22119132
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12442/3660
identifier_str_mv 22119132
url https://hdl.handle.net/20.500.12442/3660
dc.language.iso.eng.fl_str_mv eng
language eng
dc.rights.*.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_14cb
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_14cb
dc.publisher.eng.fl_str_mv The Korean Society of Nephrology
institution Universidad Simón Bolívar
dc.source.uri.eng.fl_str_mv https://doi.org/10.23876/j.krcp.18.0155
bitstream.url.fl_str_mv https://bonga.unisimon.edu.co/bitstreams/e768394f-a205-4dbd-a759-5db2a1082d79/download
https://bonga.unisimon.edu.co/bitstreams/cee6f141-aeba-4352-837a-b3bf4a0866fb/download
bitstream.checksum.fl_str_mv 4460e5956bc1d1639be9ae6146a50347
3fdc7b41651299350522650338f5754d
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv repositorio.digital@unisimon.edu.co
_version_ 1814076107108909056
spelling D´Marco, Luisa4778ac2-696a-4d29-898a-f9f4764b035eSalazar, Juanfbd053e7-5aea-424c-812f-92153ecb9181Cortez, Marie13c131c6-d238-4b67-92e7-8fe48b49082eSalazar, María15d18e94-9a11-422c-998c-cd6818c77036Lima-Martínez, Marcos9fee00f2-7c52-4239-bd7a-51155826b2d2Rojas, Edward94d56218-0c78-40f2-a501-74feeca9191cRoque, Willy1baf5d28-19a4-4abd-a12b-f0c2affbc5c0Bermúdez, Valmore29f9aa18-16a4-4fd3-8ce5-ed94a0b8663aWettel, Marjorie5de1feab-6ea5-4ecb-9dcb-b847900545952019-08-08T15:03:04Z2019-08-08T15:03:04Z201922119132https://hdl.handle.net/20.500.12442/3660Adipose tissue accumulation in specific body compartments has been associated with diabetes, hypertension and dyslipidemia. Perirenal fat (PRF) may lead to have direct lipotoxic effects on renal function and intrarenal hydrostatic pressure. This study was undertaken to explore the association of PRF with cardiovascular risk factors and different stages of chronic kidney disease (CKD). We studied 103 patients with CKD of different stages (1 to 5). PRF was measured by B-mode renal ultrasonography in the distal third between the cortex and the hepatic border and/or spleen. The PRF thickness was greater in CKD patients with impaired fasting glucose than in those with normal glucose levels (1.10 ± 0.40 cm vs. 0.85 ± 0.39 cm, P < 0.01). Patients in CKD stages 4 and 5 (glomerular filtration rate [GFR] < 30 mL/min/1.73 m2) had the highest PRF thickness. Serum triglyceride levels correlated positively with the PRF thickness; the PRF thickness was greater in patients with triglyceride levels ≥ 150 mg/dL (1.09 ± 0.40 cm vs. 0.86 ± 0.36 cm, P < 0.01). In patients with a GFR < 60 mL/min/1.73 m2, uric acid levels correlated positively with the PRF thickness (P < 0.05). In CKD patients, the PRF thickness correlated significantly with metabolic risk factors that could affect kidney function.engThe Korean Society of NephrologyAttribution-NonCommercial-NoDerivatives 4.0 InternacionalAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/http://purl.org/coar/access_right/c_14cbhttps://doi.org/10.23876/j.krcp.18.0155CardiovascularChronic kidney diseaseMetabolic riskPerirenal fatRenal insufficiencyDiabetesPerirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney diseasearticlehttp://purl.org/coar/resource_type/c_6501Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011;80:17-28.KDIGO CKD Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150.Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034-2047.Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296- 1305.Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001;16:2386-2394.Kalaitzidis RG, Siamopoulos KC. The role of obesity in kidney disease: recent findings and potential mechanisms. Int Urol Nephrol 2011;43:771-784.Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21-28.Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008;73:19-33.Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int 2017;91:1224-1235.Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010;51:1979-1987.Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009;42:1331-1346.Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab 2011;22:450-457.Bettencourt N, Toschke AM, Leite D, et al. Epicardial adipose tissue is an independent predictor of coronary atherosclerotic burden. Int J Cardiol 2012;158:26-32.D’Marco LG, Bellasi A, Kim S, Chen Z, Block GA, Raggi P. Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrol Dial Transplant 2013;28:2586-2595.Karohl C, D’Marco L, Bellasi A, Raggi P. Hybrid myocardial imaging for risk stratification prior to kidney transplantation: added value of coronary calcium and epicardial adipose tissue. J Nucl Cardiol 2013;20:1013-1020.Rea DJ, Heimbach JK, Grande JP, et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int 2006;70:1636-1641.Chughtai HL, Morgan TM, Rocco M, et al. Renal sinus fat and poor blood pressure control in middle-aged and elderly individuals at risk for cardiovascular events. Hypertension 2010;56:901-906.Montani JP, Carroll JF, Dwyer TM, Antic V, Yang Z, Dulloo AG. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord 2004;28 Suppl 4:S58-S65.Vogt FM, Ruehm S, Hunold P, et al. [Rapid total body fat measurement by magnetic resonance imaging: quantification and topography]. Rofo 2007;179:480-486. German.Tokunaga K, Matsuzawa Y, Ishikawa K, Tarui S. A novel technique for the determination of body fat by computed tomography. Int J Obes 1983;7:437-445.Stallone DD, Stunkard AJ, Wadden TA, Foster GD, Boorstein J, Arger P. Weight loss and body fat distribution: a feasibility study using computed tomography. Int J Obes 1991;15:775- 780.Armellini F, Zamboni M, Rigo L, et al. The contribution of sonography to the measurement of intra-abdominal fat. J Clin Ultrasound 1990;18:563-567.Kawasaki S, Aoki K, Hasegawa O, et al. Sonographic evaluation of visceral fat by measuring para- and perirenal fat. J Clin Ultrasound 2008;36:129-133.Sun X, Han F, Miao W, Hou N, Cao Z, Zhang G. Sonographic evaluation of para- and perirenal fat thickness is an independent predictor of early kidney damage in obese patients. Int Urol Nephrol 2013;45:1589-1595.Lamacchia O, Nicastro V, Camarchio D, et al. Para- and perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients. Nephrol Dial Transplant 2011;26:892-898.Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med 1974;81:440-447.Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85-97.de Boer IH, Sibley SD, Kestenbaum B, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 2007;18:235-243.Valensi P, Assayag M, Busby M, Pariès J, Lormeau B, Attali JR. Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 1996;20:574-579.Kim H, Kim HJ, Shin N, et al. Visceral obesity is associated with microalbuminuria in nondiabetic Asians. Hypertens Res 2014;37:679-684.Drüeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 2010;6:723- 735.Ritz E, Wanner C. Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol 2008;19:1065-1070.Scarpioni R, Ricardi M, Melfa L, Cristinelli L. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment? Cardiovasc Ther 2010;28:361-368.Wanner C, Krane V. Uremia-specific alterations in lipid metabolism. Blood Purif 2002;20:451-453.Adánez G, Castells MT, García Pérez B, et al. Effects of atorvastatin on progression-regression of renal injury in hyperlipidemic chickens. Histol Histopathol 2008;23:1131-1142.Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-1821.Kivity S, Kopel E, Maor E, et al. Association of serum uric acid and cardiovascular disease in healthy adults. Am J Cardiol 2013;111:1146-1151.Lv Q, Meng XF, He FF, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One 2013;8:e56864.Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008;19:2407- 2413.Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006;17:1466-1471.CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/e768394f-a205-4dbd-a759-5db2a1082d79/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8368https://bonga.unisimon.edu.co/bitstreams/cee6f141-aeba-4352-837a-b3bf4a0866fb/download3fdc7b41651299350522650338f5754dMD5320.500.12442/3660oai:bonga.unisimon.edu.co:20.500.12442/36602024-08-14 21:52:25.457http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalmetadata.onlyhttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.coPGEgcmVsPSJsaWNlbnNlIiBocmVmPSJodHRwOi8vY3JlYXRpdmVjb21tb25zLm9yZy9saWNlbnNlcy9ieS1uYy80LjAvIj48aW1nIGFsdD0iTGljZW5jaWEgQ3JlYXRpdmUgQ29tbW9ucyIgc3R5bGU9ImJvcmRlci13aWR0aDowIiBzcmM9Imh0dHBzOi8vaS5jcmVhdGl2ZWNvbW1vbnMub3JnL2wvYnktbmMvNC4wLzg4eDMxLnBuZyIgLz48L2E+PGJyLz5Fc3RhIG9icmEgZXN0w6EgYmFqbyB1bmEgPGEgcmVsPSJsaWNlbnNlIiBocmVmPSJodHRwOi8vY3JlYXRpdmVjb21tb25zLm9yZy9saWNlbnNlcy9ieS1uYy80LjAvIj5MaWNlbmNpYSBDcmVhdGl2ZSBDb21tb25zIEF0cmlidWNpw7NuLU5vQ29tZXJjaWFsIDQuMCBJbnRlcm5hY2lvbmFsPC9hPi4=